

Recurrent Aphthous Ulcers: A Review.

Dr. Bijo Alexander¹

Professor And Head, Department Of Oral Pathology And Microbiology, Noorul Islam College Of Dental Sciences, Aralamoodu P.O, Trivandrum 695123, Kerala, India.

Corresponding Author: Dr. Bijo Alexander

Abstract: Aphthous ulceration is a recurrent and painful inflammatory process occurring in the oral cavity due to several predisposing etiologic factors. Trauma, microorganisms, immunology, allergy and nutritional deficiencies are the commonly implicated etiologic factors. In spite of their higher prevalence, the etiopathogenesis of the condition still remains an enigma. The review presents the clinical features, diagnostic criteria, etiopathogenesis and current management protocols of this exacting condition.

Key Words: Aphthous ulcer, Pain, Trauma, Microorganisms

Date of Submission: 28-02-2019

Date of acceptance: 18-03-2019

I. Introduction

Recurrent aphthous ulcers (RAS) is a condition seen from time immemorial. The first mention of this condition was made by Hippocrates (460-370 BC) who used the word "apthai" which means "to set on fire" or to "inflammation". Recurrent aphthous stomatitis (RAS, aphthae, canker sores) is a common condition which is characterized by multiple recurrent small, round or ovoid ulcers with circumscribed margins, erythematous halos and yellow or grey flora appearing first in childhood or adolescence². Ulcers usually exhibit moderate to intense pain with healing time of 10-14 days for common type and more than two weeks for severe type. Recurrence can occur in intervals within a year or over several years³.

Epidemiology

Patil et al.⁴ in a study of aphthous ulceration in Indian population found 705 of total 3244 patients present with RAS at time of examination giving an overall prevalence of 21.7%. Females (56.3%) were more affected than males (43.7%) with standard significance. Patients in the third (20.7%) and fourth decade (26.5%) were commonly affected. Aphthae may occur for the first time in childhood but the second decade is a peak period of RAS occurrence which usually decrease with age⁵.

Clinical Features

Recurrent aphthous ulcers are extremely painful and show prodromal symptoms of tingling or burning before appearance of lesion. It can occur as one or several rounded painful ulcers at intervals of few days to few months in patients who are otherwise well². Stanley (1972)⁶ classified RAS into three different clinical variants.

1. Minor recurrent aphthae is also known as Miculicz aphthae constitute 80% of recurrent aphthae and vary in size from 8 to 10 mm. It is seen in non keratinized mucosa like labial mucosa, buccal mucosa and floor of the mouth. Ulcers heal within 10 to 14 days without scarring

2. Major aphthae also known as Suttons disease or Peradenitis mucosa necrotica constitute 10-15 percentage of aphthous ulcers. Ulcers exceed 1 cm in diameter. Lips, soft palate and fauces are involved. Ulcers persist upto 6 weeks and heal with scarring.

3. Herpetiform ulcers: Recurrent crop of ulcers upto 100 in number. Size is 2-3 mm which may coalesce to form large ulcers lasting 10-14 days. More common in women. It does not exhibit typical viral prodromal symptoms of herpetic lesions. Herpetiform ulcers involve anterior part of mouth, lip, lateral and ventral tongue, floor of mouth and rarely on lip.

Etiopathogenesis

Trauma

Trauma to oral mucosa due to local anesthetic injection, sharp tooth, tooth brush injury and iatrogenic injuries may predispose to development of RAS². It has been shown that denture wearers are usually three times more prone to RAS compared to others⁷.

Microorganisms

Various microorganisms are implicated as causative agents of RAS. Oral Streptococci was suggested as an important pathogen in recurrent aphthae either as a direct pathogen or as an antigenic stimuli in genesis of antibodies. L-form Streptococci initially typed as *Streptococcus sanguis* in recurrent aphthae was found to be *Streptococcus mutans*². A study by Hoover et.al (1986)⁸ demonstrated low levels of cross reactivity of oral Streptococci and oral mucosal antigens and considered the reactivity to be specific and clinically insignificant. *Helicobacter pylori*, a gram negative, S-shaped bacteria usually associated with gastritis and chronic duodenal ulcers has been implicated in etiopathogenesis of RAS⁹. A study by Porter et.al (1997)¹⁰ which measured the levels of IgG antibodies against *H. Pylori* in patients with recurrent aphthae showed the frequency of *H. Pylori* was not elevated significantly in recurrent aphthae patients. The role of viruses have been explored in RAS cases. Sun et.al (1998)¹¹ used PCR, Slot blot and Southern blot hybridization to show possible presence of EBV-DNA in recurrent aphthae and suggested that pre ulcerative oral aphthous ulceration may be infected with EBV. Stevenson (1967)¹² showed a negative correlation of recurrent aphthae and lactobacillus activity.

Genetic Factors

Family history of aphthous stomatitis is seen in 24-36% of RAS patients¹³. The presence of aphthae in parents significantly influences the risk of RAS development and course of disease in offspring. Risk of aphthae reaches 90% in patients with both parents affected compared to 20% in children with healthy parents¹⁴. Alteration in cytokine metabolism including interleukins (IL-1 β , IL-2, IL-4, IL-5, IL-6, IL-10, IL-12), Interferon- γ and TNF- α , serotonin transporter gene and endothelial nitric oxide synthetase gene was analyzed. Elevated concentration of m-RNA corresponding with IL-2, IFN- γ and TNF- α and decreased m-RNA levels corresponding with IL-10 was detected in aphthous patients¹⁵. Certain HLA groups identified with RAS include HLA-A2, HLA-B5, HLA-B44, HLA-B12, HLA-B51, HLA-B52, HLA-DR2, HLA-DR7 and HLA-DQ series. Since no HLA is consistently associated with RAS, studies are inconclusive¹⁶.

Immunologic Factors

Immunologic factors has often been implicated in etiopathogenesis of RAS. Savage et.al used monoclonal antibodies directed against T-lymphocyte surface antigens (OKT, OKT4 and OKT8) to investigate changes in T-cell sub population in RAS. Ulcerative lesions contained a large number of OKT8 positive suppressor/cytotoxic cells and a very small number of OKT4 positive cells supporting the role of lymphotoxicity in establishment of RAS. Bachtiar et.al¹⁸ analysed proportions of CD3+(T cell), CD4+(helper T cell), CD8+(suppressor/cytotoxic cell), CD19+(B cell) and CD 16+/CD56+(NK cell) groups. RAS was associated with abnormal population of CD4+ and CD8+ cells.

Allergic Factors

Allergy has been suspected as a cause of RAS especially due to hypersensitivity to certain food substances. Foods like milk and milk products¹⁹, almonds, tomatoes and wheat flour are implicated in RAS.²⁰. Sequential elimination of milk, cheese and wheat has been found beneficial for some patients. Quian et.al²² investigated the occurrence of RAS among college students and its potential effect on dietary habits in students at Beijing University of Chinese Medicine. They concluded that students using frequent carbonated beverages or had frequent thirst had a higher incidence of RAS while use of nuts afforded protection. A study to investigate the effects of sodium lauryl sulfate (SLS), a synthetic detergent in dentifrices on RAS patients for 3 months followed by dentifrice without sodium lauryl sulfate showed a statistically significant decrease in number of aphthous ulcers in patients using SLS free dentifrice. It is suggested that effect of SLS on the oral mucin layer with exposure of the underlying epithelium induces RAS²³. Another recent study showed that the number of ulcers and episodes did not differ between SLS free dentifrice and SLS containing dentifrice²⁴.

Nutritional Deficiency

RAS can also result from a nutritional deficiency particularly lack of iron, vitamin B3, vitamin C, folic acid or vitamin B12²⁵. Some nutritional deficiency can occur along with other diseases such as malabsorption syndrome or gluten sensitivity with or without enteropathy²⁶. Full hematologic screening of RAS patients should be done to identify latent deficiency states so that the underlying causes can be elucidated and corrected especially in vitamin B12 deficiency²⁷.

Psychologic factors

Stress has been proposed as an important cause of RAS. Gallo et.al in their study in RAS patients supported the role of stress in RAS patients²⁸. Psychological stress may act as a trigger or modifying factor rather than an emotional factor in RAS. Miller et.al²⁹ in a study of 1788 professional students from the University of

Pennsylvania showed prevalence rate of 48.3% in men and 57.2% in women during their period of study but decreased considerably once they became practicing professionals.

II. Allied Medical Conditions

Behchets syndrome

It is similar to RAS but with multiple system involvement including recurrent genital ulceration, ocular and cutaneous diseases and a range of renal, GIT, joint and hematologic abnormalities. Both genetic and environmental factors are involved in development of Behchets syndrome. The disease is assumed to stem from an autoimmune response which in turn may be triggered by infection or other environmental agents in genetically susceptible individuals³⁰.

PFAPA syndrome

The syndrome of periodic fever, aphthous stomatitis, pharyngitis and cervical adenitis is the most common cause of periodic fever in childhood. Usually PFAPA syndrome resolves during adolescence but there is increasing evidence that the condition may persist into adulthood³¹.

Sweet syndrome

Originally described by Dr. Robert Douglas Sweet, it is characterized by acute febrile neutrophilic dermatosis syndrome characterized by pyrexia, elevated neutrophil count, nodules, plaques, painful red papules and an infiltrate consisting of predominantly mature neutrophils in upper dermis. It is seen usually in middle aged females, 50% of patients develop associated malignancy (AML)³².

MAGIC Syndrome

MAGIC syndrome (Mouth and Genital ulcers with inflamed Cartilage) has been proposed to describe patient with clinical features of both relapsing polycondritis and Behchets disease³³.

HIV

In HIV patients, persistent, painful ulcers can occur on soft palate, buccal mucosa, tonsillar pillars or tongue with symptoms more severe than non HIV patients. RAS is usually delayed in patients with CD4+ lymphocyte count below 100 cells/mm³ but it can also be a pointer to an impending HIV infection³⁴.

Chrons disease

60% of patients with Chrons disease present with oral manifestations including chelitis, oral ulcerations fissuring and glossitis and this can be the first sign of disease in 5-10% cases³⁵.

Treatment

The treatment of RAS depends on the frequency, number and size of ulcers. The treatment should be governed by the disease severity, frequency of occurrence and medical history of the patient³⁶. Small lesions are usually treated by lidocaine 1% cream, polidocanol paste and benzocaine lozenges. Mouth wash of Benzocaine and Cetylpyridinium has shown good results. Other topical agents that can minimize patient discomfort include diclofenac, a NSAID or amelxanox paste which has been shown to decrease healing of minor apthae³⁷. Topical antibiotics such as tetracycline and their derivatives like minocycline and doxycycline in gel or rinse form often decreases the pain due to local inhibition of collagenases and metalloproteinases³⁸. Most widely used drugs in RAS is topical corticosteroids because it suppresses the pain, reduces healing time and eliminate symptoms. Triamcinolone acetonide, Flucocinolone acetonide and Clobelastol propionate are used³⁹. Pentoxifylline, inhibitor of TNF- α and of neutrophil function and chemotaxis has been beneficial in patients with RAS. Due to several side effects especially in GIT, it should be used as a second line treatment option in patients that fail to respond to other therapies⁴⁰. Immunomodulators like thalidomide have been used for treatment of RAS at a dose of 50-100 mg/day and has shown complete remission in 85% of patients in a study. Thalidomide however exhibits many adverse effects like teratogenicity, polyneuropathy, drowsiness, headache, nausea and gastric pain⁴¹. Levimasole, another immunomodulator restores normal phagocytic activity among macrophages and neutrophils and modulates T cell mediated immunity. Drug dose of 150 mg, three times a week for six months reduce the number, size and frequency of attacks. Adverse effects include nausea, dysguesia and agranulocytosis⁴².

For better management strategies, RAS may be classified in three clinical presentations: Type A, Type B and Type C.

Type A: Usually occur sporadically in a year with tolerable pain levels. The dietary history of the patient should be analysed. Hard foods, all types of nuts, chocolate, acid beverages, alcohol and spicy foods should be

avoided. Predisposing factors like local trauma, tooth brush injury should be prevented and the patient advised regarding this matter⁴³.

Type B: Episodes lasting 3-10 days occur monthly. The predisposing factors should be identified and controlled along with diet and habit modification. It is important to identify prodromic manifestations like itch or swelling and provide topical treatment as and when it occurs⁴³.

Type C: Chronic aphthae with painful episodes. While some lesions heal others develop and the patient is never free of lesions. Systemic therapy is usually indicated since topical therapy is unsuccessful⁴³.

III. Conclusion

Even though aphthous stomatitis is a widely studied lesion lot of grey areas exist in the etiopathogenesis and diagnosis of this condition. Even though topical and systemic medicaments are useful in controlling RAS symptoms, it often interferes in the well being of the patients. A treatment protocol may aid the clinicians in determining the appropriate treatment for the patient.

Acknowledgement: Nil.

Conflict of interest: None reported.

References

- [1]. Compilato D, Carroccio A, Calvino F, DiFede G, Campisi G. (2010). Hematological deficiencies in patients with recurrent aphthosis, *J Eur Acad Dermatol Venerol*. Vol 24(6):667-73.
- [2]. Jurge S, Kuffer R, Scully C, Porter SR. (2006). Mucosal Disease Series Number V1-Recurrent Aphthous Stomatitis. *Oral Diseases*, Vol 12, 1-21.
- [3]. Kramer IR, Pindborg JJ, Bezroukov V, Infirrin JS. (1980) to epidemiology and diagnosis of oral mucosal diseases and conditions. *WHO Community Dent Epidemiol* Vol 8:1-26.
- [4]. Patil S, Reddy SN, Maheswari S, Khandelwal S, Shruthi D and Doni B. (2014) Prevalence of recurrent aphthous ulceration in Indian population. *Journal of Clin Exp. Dent*. Vol 6(1):36-40.
- [5]. Szpanav E, Slebioda Z, Mania-Konsko A. (2006). Recurrent aphthous stomatitis in patients attending Department of Oral Mucosal Diseases of Poznam Medical University on the basis of 10 years observation. *Czas Stomatol*; Vol 61; 488-94.
- [6]. Stanley HR (1972). Aphthous lesions. *Oral Surg Oral Med Oral Pathol* Vol 30: 407-16.
- [7]. Espinoza I, Rojas R, Aranda W, Gamonal J. (2003). Prevalence of oral mucosal lesions in elderly people in Santiago, Chile. *J Oral Pathol Med*, Vol 32:571-575.
- [8]. Hoover CI, Olson JJ, Grenspan JS. (1986) Humoral responses and cross reactivity of viridans streptococci in RAU. *J Dent Res*. Vol 65:1101-1104.
- [9]. Shimoyama T, Horie N, Kato T, Kaneko T, Komiyama K. (2000). *Helicobacter pylori* in oral ulcerations. *J Oral Sci* Vol 42:225-229.
- [10]. Porter SR, Barker GR, Scully C, Macfarlane G, Bain L. (1977). Serum IgG antibodies in H. Pylori in patients with recurrent aphthous stomatitis and other disorders. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod*, Vol 83:325-8.
- [11]. Sun A, Chang JG, Chu CT, Liu BY, Yuan JH, Chiang CP. (1998) Preliminary evidence for an association of EBV with preulcerative oral lesions in patients with recurrent aphthous ulcers or Behcets disease. *J Oral Pathol Med*. Vol 27(4):168-75.
- [12]. Stevenson G. (1967). Evidence for a negative correlation of RAU with lactobacillus activity. *J La Dent Assoc*. Vol 25:5-7.
- [13]. Natak SS, Kontinen YT, Enattah NS. (2008) Recurrent aphthous ulcers today: A review of growing knowledge today. *Int J Oral Maxillofac Surg* Vol 46:198-206.
- [14]. Rogers RS. (1997). Recurrent aphthous stomatitis: Clinical characteristics and associated systemic disorders. *Seminars in Cutaneous Medicine and Surgery*. Vol 16:278-83.
- [15]. Buno JJ, Huff C, Weston WL et al. (1998). Elevated levels of Interferon γ , TNF- α , Interleukin 2, 4, 5 but not interleukin 10 are present in recurrent aphthous stomatitis. *Arch Dermatol*; Vol 134:87-31.
- [16]. Savage NW, Seymour GJ, Kruger BJ. (1986). Expression of Class I and Class II MHC antigens on epithelial cells in recurrent aphthous stomatitis. *J Oral Pathol* Vol 15:191-195.
- [17]. Savage NW, Seymour GJ, Kruger BJ. (1985). T-lymphocyte subset changes in recurrent aphthous stomatitis. *Oral Surg Oral Med Oral Pathol*. Vol 60(2):175-81.
- [18]. Bachtar EW, Cornair S, Siregar B, Raharjo TW. (1998). Decreased CD4+/CD8+ ratio in major types of aphthous ulcers: Comparing major and minor types of ulcers. *Asian Pac J Allergy Immunol*. Vol 16(2-3):75-79.
- [19]. Wang X, Li X, Shi H (2017). Analysis of recurrent oral ulcers in patients with or without food allergy. *Biomedical Research* Vol 28(8);3490-94.
- [20]. Eversole LR, Shopper TB, Chambers DW. (1982). Effects of suspected foodstuff challenging agents in the etiology of recurrent aphthous stomatitis. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod* Vol 54:33-38.
- [21]. Hay KD, Raede PC. (1984). The use of elimination diet in the treatment of recurrent aphthous stomatitis of the oral cavity. *Oral Med Oral Pathol Oral Radiol Endod* Vol 57:504-7.
- [22]. Qian DU, Shenglon N, Yanling Fu and Shanhai Lin. (2018). Analysis of Dietary related Factors of Recurrent Aphthous Stomatitis among College Students. *Evidence Based Complementary and Alternative Medicine*. Article ID 2907812, 7 Pages.
- [23]. Herlofson BB, Barkvold P. (1994) Sodium lauryl sulfate and recurrent aphthous stomatitis. A preliminary study. *Acta Odontol Scand* Vol 52(5):257-9.
- [24]. Shin YJ, Choi JH, Ahn HJ, Kwon JS (2012). Effect of sodium lauryl sulfate on recurrent aphthous stomatitis: A randomised controlled trial. *Oral Dis* Vol 18(7):655-60.
- [25]. Piskin S, Sayan C, Darukan N, Senol M. (2002). Serum iron ferritin, folic acid and Vit B12 levels in recurrent aphthous stomatitis. *J Eur Acad Dermatol Venerol*, Vol 16:66-7.
- [26]. Wray D, Fergusson MM, Hutcheon AW, Dagg JH (1978). Nutritional deficiencies in recurrent aphthae. *J Oral Pathol Med* Vol 20:389-91.
- [27]. Porter SR, Scully C, Flint S (1988). Hematological studies in recurrent aphthous stomatitis compared to other oral diseases. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod* Vol 66(1):41-4.
- [28]. Gallo CB, Mimura MA, Sugaya MN. (2009). Psychological stress and recurrent aphthous stomatitis. *Clinics (Sao Paulo)* Vol 64(7):645-648.

- [29]. Miller MF, Ship II. (1977). A retrospective study of the prevalence and incidence of recurrent aphthous ulcers in a professional population, 1958-1971. *Oral Surg Oral Med Oral Pathol* Vol 43(4):532-7.
- [30]. Zeiden MJ, Saadoun D, Garrido M (2016). Behçet's disease pathophysiology: a contemporary review. *Auto Immun Highlights*, Vol 7(1)4.
- [31]. Vanoni F, Theodoropoulou K, Hofer M (2016). PFAPA syndrome: A review on treatment and outcome. *Pediatric Rheumatology* Vol 14:38.
- [32]. Cohen PR, Kurzrock R (2002). Sweet Syndrome: A review of current treatment options. *Am J Clin Dermatol* Vol 3(2):117-31.
- [33]. Ng CS, Hogan P, McKenzie S, Gibbs H, Stratton G, Wong R. (2007). Mouth and Genital Ulcers with inflamed Cartilage (MAGIC) syndrome complicated by aneurysmal aortitis. *J Clin Rheumatol* Vol 13(4):221-3.
- [34]. Kerr AR, Ship JA (2003). Management strategies associated with aphthous stomatitis. *Am J Dermatol*, Vol 4:669-80.
- [35]. Kalla R, Ventham NT, Satsangi J, Arnott IDR. (2014). Crohn's disease. *the BMJ*;349:g6670.
- [36]. Scully C, Gorsky M, Lozada-Nur F. (2003) The diagnosis and management of recurrent aphthous stomatitis. A consensus approach. *J Am Dent Assoc* 34:200-7.
- [37]. Descorix V, Coudent AE, Vige E et al. (2011). Efficacy of 1% topical lidocaine in the symptomatic treatment of pain associated with oral mucosal trauma or minor aphthous ulcer: a randomized, double-blind, placebo-controlled, parallel group, single-dose study. *J Orofac Pain* 25(4):327-32.
- [38]. Baccaglini L, Lalla RV, Bruce Aj, Sartori-Valinotti JC et al. (2011). Urban legends Series: Recurrent Aphthous Stomatitis. *Oral Dis* 17(8):755-770.
- [39]. Quijano D, Rodriguez M (2008). Topical corticosteroids in recurrent aphthous stomatitis. A systemic review. *Acta Otolaryngol Esp*, Vol 59:298-307.
- [40]. Scully C, Porter S. (2008). Oral mucosal disease: Recurrent aphthous stomatitis. *Br J Oral Maxillofac Surg*. Vol 46:198-206.
- [41]. Hello M, Barbarot S, Bastuji-Garin S, Reviz J, Chosidow O. (2010). Use of thalidomide for severe recurrent aphthous stomatitis: A multicenter cohort analysis. *Vol 8: Medicine (Baltimore)* 176-82.
- [42]. Weckx LL, Hirata CH, Abreu MA, Fillizolla VC, Silva OM (2009). Levamisole does not prevent lesions of Recurrent aphthous stomatitis: A double-blind placebo-controlled clinical trial. *Rev Assoc Med Bras*. Vol 55:132-8.
- [43]. Gualler IB, Soriano YJ, Locano AC. (2014). Treatment of recurrent aphthous stomatitis. A literature review. *J Clin Exp Dent*. Vol 6(2):e 168-e 174.

Dr. Bijo Alexander. "Recurrent Aphthous Ulcers: A Review." *OSR Journal of Dental and Medical Sciences (IOSR-JDMS)*, vol. 18, no. 3, 2019, pp 16-20.